Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0334 Phase 1 study in healthy volunteers
NCT03381144Phase 1Terminated
- Sponsor
- Genentech
- Start
- Dec 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GDC-0334 in asthma (6 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants with Adverse Events at 42 days, Severity of Adverse Events per WHO Toxicity Grading Scale at 42 days and 7 more. Started Dec 2017; status: terminated.
02
Drugs
GDC-0334
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03381144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381144.